Each morning the deterministic engine ranks the universe and an analyst model writes up the top setups; a separate red-team model then tries to disprove every claim. Only notes that survive with a publish or publish with caveats verdict appear here. Free readers see the headline and what happened; the full note is in the Pro digest.
On 2 September 2026, Senti disclosed receipt of a Nasdaq Staff Delisting Determination Letter citing failure to cure minimum bid price, equity deficiency (now -$3.4M at 30 June 2026), and stockholders' equity below $2.5M; the company requested a Hearings Panel. On 4 September 2026 Senti amended its securities purchase agreement and filed an equity commitment letter referencing stockholders' equity deficiency, indicating ongoing PIPE negotiations. An S-3/A shelf amendment was filed 10 September 2026, and a Schedule 13D/A on 11 September 2026 suggests related-party participation.
My Size, Inc. (MYSZ) disclosed on August 28, 2026 that it has been summoned to a Nasdaq Hearings Panel and faces stockholders' equity deficiency alongside previously disclosed listing violations. The company's June 30, 2026 10-Q (now 84 days stale) reported cash of $453,000 against current liabilities of $3.3 million, yielding approximately 1.3 months of runway based on recent operating cash flow burn of $4.1 million annualized. On September 16, 2026, the company executed an equity line of credit agreement and disclosed PIPE and ATM references in a multi-item 8-K that also mentions a reverse split.
GoPro disclosed $27.3 million cash as of June 30, 2026, against annualized operating cash burn of $96.1 million—implying approximately 3.4 months of runway. Between September 1 and September 17, 2026, the company filed a new convertible-note exhibit (8-K, September 8), eight prospectus supplements (424B3), and an unregistered-sale 8-K (Item 3.02), while also disclosing reverse-split language in September 2 and September 8 exhibits and a Nasdaq minimum-bid deficiency notice on September 17. Meanwhile, a Schedule 13D was filed September 9, indicating a new activist holder acquired a stake during this distressed period.
GeoVax Labs (CIK 832489) disclosed on 28 August 2026 that Nasdaq's Hearings Panel had ruled on its listing deficiencies (8-K filed 28 Aug 2026, Item 3.01) and simultaneously closed an equity-line facility and warrant-inducement transaction (8-K filed 28 Aug 2026, Item 3.02). The company reported $3.1 million cash as of 30 June 2026 against approximately $14.6 million annualized operating cash outflow, implying roughly 2.6 months of runway from that date—now 84 days stale. Outstanding share count jumped 112 percent from 3.47 million (14 May 2026) to 7.37 million (27 July 2026), and multiple filings reference reverse splits, minimum-bid deficiencies, and stockholders' equity deficiency.
AZIO AI HOLDINGS (AZIO), a motor vehicle parts company with $2.0 million cash and ~4.3 months of runway (as of March 31, 2026 10-Q; now 175 days stale), received a Nasdaq delisting notice on August 28, 2026 and changed auditors on September 10, 2026. The company has negative stockholders' equity of -$8.2 million as of March 31, 2026, and its public float of $6.4 million (as of June 30, 2025) hovers near the $5 million MVLS floor. Three officer departures occurred in 90 days (latest September 14, 2026), convertible-note references appear in an amended 8-K filed September 15, 2026, and a preliminary proxy filed September 18, 2026 references a reverse-split proposal.
On September 17, 2026, Stardust Power (SDST) disclosed in an 8-K that it received notice from Nasdaq's Hearings Panel regarding Market Value of Listed Securities (MVLS) and minimum bid price deficiencies, explicitly referencing delisting risk. The next day, the company filed its 27th 424B5 prospectus supplement in the past twelve months, continuing an active at-the-market equity offering program. As of June 30, 2026 (the most recent balance sheet, now 80 days stale), the company held $540,264 in cash against $14.93 million in current liabilities, yielding an estimated 0.8 months of runway based on annualized operating cash outflows of $8.1 million.
Profusa, Inc. (PFSA), a medical-device maker with a $1.3M public float and negative $28.2M equity (as of March 31, 2026), executed three separate equity-line and convertible-note transactions on August 12, September 1, and September 16, 2026. The company received a Nasdaq delisting notice on August 26 (disclosed August 31, 8-K) for failing to file its Form 10-Q on time, coming on top of earlier minimum-value-of-listed-securities deficiencies. A Schedule 13D filed August 19 showed a new activist holder taking a >5% position.
Nexalin Technology filed two equity-line agreements and an ATM program on August 20 and 21, 2026, simultaneously disclosing a convertible note in an 8-K Item 2.03 (Financial Obligation) and a registered direct offering via prospectus supplement on August 20. The company executed a 1-for-10 reverse split on August 26 and filed a fresh S-1 shelf on September 3. Cash as of June 30, 2026 was $1.0 million against an annualized burn of $7.1 million (1.7 months runway), now 80 days stale. A new Schedule 13D activist appeared September 3.
authID Inc. disclosed two Item 3.01 listing notices in August 2026: on August 21 it received a non-compliance letter for failing to maintain $50 million in market value of listed securities (MVLS) and for stockholders' equity below $2.5 million, and on September 1 it disclosed a second notice for minimum bid price non-compliance and its request for a hearings panel. Both 8-Ks reference going concern and the August 21 filing arrived late Friday evening. On September 15, the company filed an Item 3.02 for an unregistered securities sale referencing convertible notes and a PIPE. As of June 30, 2026 (79 days stale), authID held $1,350,631 in cash against $5,278,317 in current liabilities and equity of $2,042,515, implying approximately 1.2 months of runway based on annualized operating cash flow.
XCF Global, Inc. (SAFX) filed an NT 10-Q on August 17, 2026, acknowledging the late filing of its Q2 10-Q for the period ending June 30, 2026. The quarterly report itself followed hours later but disclosed a going-concern opinion and liquidity of $1.05 million against current liabilities of $244.8 million as of March 31, 2026. Between August 18 and September 8, 2026, the company entered into at least two convertible note agreements (per 8-Ks), filed three shelf registrations (S-1 on August 19, S-3 on September 10, amended S-3 on September 15) that went effective August 27, and disclosed an at-the-market equity offering program on September 15. On September 14, 2026, the company filed an 8-K disclosing receipt of a Nasdaq minimum-bid deficiency notice, and on September 15 a Schedule 13D was filed by an unidentified third party. The company executed three unregistered securities sales (Item 3.02 8-Ks on August 18, September 14, and September 16) and references to reverse splits appeared in multiple convertible-note exhibits.
On August 25, 2026, Datavault AI disclosed in an 8-K (Item 3.01) that it requested a hearing before a Nasdaq Hearings Panel following a delisting determination, citing continued non-compliance with Nasdaq's minimum bid price requirement. The company previously received multiple listing notices and has executed reverse splits. Simultaneously, the company closed a PIPE transaction (8-K dated August 19, 2026) and established an ATM program while carrying a going-concern opinion in the 10-Q filed August 19, 2026. The March 31, 2026 balance sheet showed $2.2 million in cash against $23.0 million in current liabilities, implying approximately 1.1 months of runway based on trailing twelve-month operating cash outflow of $23.6 million.
On August 21, 2026, Adial Pharmaceuticals disclosed in an 8-K (Item 3.01) that it received a Nasdaq delisting notice for failing both the $5 million Minimum Value of Listed Securities (MVLS) standard and the stockholders' equity standard. The company had $28.7 million cash and negative $38.4 million equity as of June 30, 2026, implying approximately 21 months of runway. Reverse-split proposals appeared in preliminary and definitive proxy materials filed August 11 and August 24, and a shelf registration (S-3) was filed August 28.
Expion Energy (XPON), a sub-$5M microcap electrical equipment manufacturer, reported $1.54 million cash and ~3.5 months of runway as of June 30, 2026, based on annualized 180-day YTD operating cash flow of $5.3 million. On August 24, 2026, the company executed both an equity-line agreement (common stock purchase agreement) and disclosed a reverse stock split effective that date, while on August 7 an 8-K exhibit referenced Nasdaq minimum bid deficiency. Four Item 5.02 officer/director departure filings appeared over 90 days (latest August 31), and a Schedule 13D was filed August 28 showing a new activist holder.
Reliance Global Group, Inc. (Nasdaq: EZRA), an insurance services firm with ~$1.8 million cash as of June 30, 2026, has triggered multiple distress signals across a 30-day window in August 2026. On August 4 the company disclosed (8-K, ex-99.1) references to an equity line of credit, ATM program, minimum bid deficiency, and a reverse split; on August 6 an unregistered sale (8-K Item 3.02) followed; on August 27 an activist Schedule 13D was filed and a fresh S-1 shelf registration appeared; by August 31 that shelf was declared effective. The balance-sheet snapshot (Q2 2026) shows ~$1.8 million liquidity against an annualized burn of ~$4.5 million—implying a 4.8-month runway—and equity of $6.7 million supported by only ~1.0 million shares outstanding after a dramatic decline from 22.2 million shares in May.
On August 14, 2026, HCW Biologics filed an 8-K (Item 4.02) announcing that its Q1 2026 financials cannot be relied upon due to a material EPS misstatement. The company failed to properly apply the two-class method, overstating basic/diluted EPS by $0.80 per share (post-split) by allocating 100% of undistributed earnings to common stock instead of ~63% to common and ~37% to participating securities. Management concluded a material weakness exists in technical accounting review controls over complex warrant instruments. The same day, a press-release exhibit disclosed the company is before a Nasdaq hearings panel. Meanwhile, on July 29, the company completed a $1.6M private placement selling 218,682 shares and 400,000 pre-funded warrants (plus rights to common warrants subject to stockholder approval). Insiders—CEO Wong, Chairman Garrett, and SVP Flowers—participated. The Q2 10-Q filed August 14 shows $741,324 cash against $18.6M current liabilities as of June 30, indicating ~0.8 months of runway.
On August 14, 2026, Worksport disclosed receipt of a Nasdaq minimum bid price deficiency notice (8-K Item 3.01), triggered by 30 consecutive trading days below $1.00, giving the company until February 9, 2027 to regain compliance. The company has approximately 0.6 months of cash runway based on $1.16 million liquidity as of June 30, 2026 and an annualized burn rate of $23.7 million. Concurrently, Worksport filed an amended ATM prospectus supplement on August 7, 2026 for up to $493,000 of common stock sales under its September 2022 Sales Agreement with H.C. Wainwright, and disclosed an equity line financing arrangement and warrant inducement on August 27, 2026 (8-K Item 1.01/3.02).
bioAffinity Technologies (BIAF) disclosed on July 31, 2026 that Nasdaq issued a delisting notice for failing to maintain a minimum bid price above $1.00 for 30 consecutive days; the company is ineligible for any compliance period because it executed a 1-for-30 reverse split in September 2025 (Nasdaq rules permit one reverse split per 12 months). Two weeks later, on August 14, 2026, the company closed a $4M private placement of pre-funded warrants at $0.4657 plus accompanying Series A and B warrants (200% coverage) exercisable at $0.4727 (contingent on stockholder approval), with WallachBeth as placement agent. The 10-Q for Q2/2026 (filed August 7) showed cash of $2.4M as of June 30, 2026, implying approximately 2.2 months of runway based on annualized 180-day operating cash burn of $13M.
Freenome Holdings completed its de-SPAC transaction with Perceptive Capital Solutions Corp on July 20, 2026, raising gross proceeds of approximately $310.3 million ($70.3M from trust, $240M PIPE), and began trading on Nasdaq under ticker FRNM following a reverse split. The complex 8-K filed July 24, 2026 disclosed simultaneous auditor change (Item 4.01), control change (Item 5.01), officer departure (Item 5.02), rights modification (Item 3.03), unregistered securities sales (Item 3.02), and reverse split (Item 5.03), all accepted after hours on a Friday evening. An S-1 shelf registration was filed August 18, 2026 and declared effective July 29, 2026 (an apparent chronological inconsistency in the filing system), while June 30, 2026 financials show cash of $437k, negative equity of -$6.3M, and estimated runway of 6.1 months based on annualized operating cash outflow.
Cycurion, Inc. (CYCU), a McLean-based cybersecurity services provider, disclosed in its 10-Q filed August 14, 2026 (for the quarter ended June 30, 2026) that it held $1.87 million in cash against $19.5 million in current liabilities, yielding an estimated 1.8-month runway based on annualized six-month operating cash outflow of $12.5 million. Between July 30 and August 3, 2026, the company induced exercise of existing warrants for ~$4.5 million gross proceeds by lowering the strike from $3.62 to $1.35 and issuing new warrants at $1.65 (150% coverage, five-year term, subject to shareholder approval), effectively front-loading cash at the cost of future dilution. Concurrently, the company faces a Nasdaq hearings panel on August 20, 2026 to appeal a minimum-bid delisting notice, having already executed a 1-for-20 reverse split on July 23, 2026; shares outstanding jumped 141% to 25.8 million by August 10, 2026.
On July 23, 2026, BOXABL Inc. (formerly FG Merger II Corp.) closed its SPAC merger. The same 8-K disclosed a change of auditor (Item 4.01), Nasdaq listing deficiency notice (Item 3.01), termination of prior agreements (Item 1.02), officer departures (Item 5.02), control changes (Item 5.01), shareholder rights modifications (Item 3.03), unregistered securities issuance (Item 3.02), and going-concern language in the audited financials. Two Schedule 13Ds were filed July 24. On August 17, BOXABL filed NT 10-Q, reporting it could not file its Q2 2026 10-Q on time. BOXABL subsequently filed S-3 shelf registrations on July 27 (declared effective August 10), seeking to register up to $500M in securities.
Outlook Therapeutics closed a $55M public offering on August 14, 2026, selling 55,555,556 shares with accompanying warrants at $0.99 combined price (~$51.1M net proceeds after fees). This followed FDA approval of LYTENAVA in July 2026 for wet AMD treatment. Concurrently, four insiders executed open-market purchases totaling ~$2.6M between July 29 and August 14, including CEO Bob Jahr (151,515 shares at $0.00) and largest holder Ghiath Sukhtian (2,525,252 shares at $0.99). The company reported $11.2M cash as of June 30, 2026 (preliminary, unaudited), implying ~2 months runway based on $45.9M annualized burn from the March 31, 2026 10-Q (now 140 days stale).
VivoSim Labs received a Nasdaq notice on July 24, 2026, stating it failed to maintain the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1), based on its March 31, 2026 fiscal year-end equity deficit of $(1.1) million. The company must submit a compliance plan by September 3, 2026, and may receive up to 180 days (until January 16, 2027) to cure. Despite closing a $4 million PIPE on July 17, 2026, and receiving a $5 million milestone payment from Eli Lilly in July 2026 (both post-balance-sheet events), the June 30, 2026 balance sheet still showed negative equity of $(2.3) million and cash of $1.67 million against a $10.8 million annual burn rate.